Novavax To Evaluate Swine Flu Vaccine

Novavax Inc. (Nasdaq: NVAX) will work with the National Institutes of Health to evaluate a virus-like particle vaccine against the swine flu, influenza A (H1N1), virus. Shares of the biopharmaceutical jumped $1.00 to $2.87.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.